Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide

Journal of Clinical Gastroenterology

Volumn 44, Issue 7, 2010, Pages 504-509

  Rossignol, Jean Francois ^a,b   Elfert, Asem ^c   Keeffe, Emmet B ^a,b  

^a Romark Institute for Medical Research   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

chronic hepatitis C; HCV; nitazoxanide; peginterferon; ribavirin

Indexed keywords

NITAZOXANIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; THIAZOLE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LEUKOPENIA; MALE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HEPATITIS C, CHRONIC; MIDDLE AGED; PILOT STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955146829     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181bf9b15     Document Type: Article

References (20)

1. World Health Organization. Hepatitis C. Fact Sheet Number 164, revised October 2000. Available at: http://www.who.int/ mediacentre/factsheets/fs164/en. Accessed March 2, 2009.
2. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of chronic hepatitis C: an update. Hepatology. 2009;49:1335-1374.
3. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231-264.
4. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology. 2008;47:1371-1383.
5. Keeffe EB. Future treatment of chronic hepatitis C. Antivir Ther. 2007;12:1015-1025.
6. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313-320.
7. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol. 2008;3:539-545.
8. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs. 2007;67: 1947-1967.
9. Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008;77:56-63.
10. Schaninger T, Hong J, Luo GG. Nitazoxanide inhibits hepatitis C virus replication in vitro [abstract]. Hepatology. 2008;48:756A.
11. ElazarM, LiuM,McKenna SA, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2a via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009;137:1827-1835.
12. Rossignol JF, Kabil SM, El-Gohary Y, et al. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment Pharmacol Ther. 2008;28:574-580.
13. Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in chronic hepatitis C genotype 4 patients treated with nitazoxanide, peginterferon and ribavirin. Gastroenterology. 2009;136:856-862.
14. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report [abstract]. Hepatology. 2008;48:344A-345A.
15. AIDS Clinical Trials Group. AIDS Clinical Trials Group (ACTG) Toxicity Grading Scale. Silver Spring, MD: AIDS Clinical Trials Group; 1996.
16. Knodell RG, Ishak KJ, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
17. Goodman ZK, Ishak JG. Histopathology of hepatitis C virus infection. Sem Liv Dis. 1995;15:71-81.
18. Hoffman PS, Sission G, Croxen MA, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007; 51:868-876.
19. Korba BE, Elazar M, Lui P, et al. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52:4069-4071.
20. Bacon B, Shiffman M, Lim J, et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in SVR [abstract]. J Hepatol. 2009;50:S381.